Niagen Bioscience
NAGE
96 hedge funds and large institutions have $211M invested in Niagen Bioscience in 2021 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 24 increasing their positions, 33 reducing their positions, and 16 closing their positions.
177% more capital invested
Capital invested by funds: $76.1M → $211M (+$135M)
81% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 16
16% more funds holding
Funds holding: 83 → 96 (+13)
8.16% more ownership
Funds ownership: 25.68% → 33.84% (+8.2%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
11% less call options, than puts
Call options by funds: $8.87M | Put options by funds: $9.92M
27% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 33
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
YRHAM
Yong Rong (HK) Asset Management
Sheung Wan,
Hong Kong
|
+$32.7M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$11.2M |
| 3 |
Millennium Management
New York
|
+$6.44M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$6.43M |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$4.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tieton Capital Management
Yakima,
Washington
|
-$6.68M |
| 2 |
SA
Sycale Advisors
New York
|
-$3.43M |
| 3 |
UIC
Uniplan Investment Counsel
Milwaukee,
Wisconsin
|
-$3.27M |
| 4 |
IC
Iconiq Capital
San Francisco,
California
|
-$3.26M |
| 5 |
Morgan Stanley
New York
|
-$2.84M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
HSBC Holdings
London,
United Kingdom
| – | -$136K | -28,057 | Closed |
|
|
AG
102
Algert Global
San Francisco,
California
| – | -$131K | -27,340 | Closed |
|
103
Two Sigma Advisers
New York
| – | -$105K | -21,800 | Closed |
|
|
CS
104
Credit Suisse
Zurich,
Switzerland
| – | -$63K | -13,147 | Closed |
|
|
HW
105
Hancock Whitney
Gulfport,
Mississippi
| – | -$60K | -12,528 | Closed |
|
|
AIP
106
Ahrens Investment Partners
Lafayette,
Louisiana
| – | -$53K | -11,000 | Closed |
|
|
PP
107
PDT Partners
New York
| – | -$52K | -10,738 | Closed |
|
108
Principal Financial Group
Des Moines,
Iowa
| – | -$51K | -10,521 | Closed |
|
|
PCA
109
Peddock Capital Advisors
Braintree,
Massachusetts
| – | -$16K | -3,380 | Closed |
|
|
LGA
110
Lebenthal Global Advisors
Hauppauge,
New York
| – | -$4K | -934 | Closed |
|
|
RE
111
RBC Europe
London,
United Kingdom
| – | -$797 | -166 | Closed |
|
NAGE Hedge Fund Activity: Q1 2021 in Review
96 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Niagen Bioscience (NAGE) for Q1 2021, worth a combined $211M — up 177% from $76.1M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new NAGE positions and 16 closed out — a net gain of 13 holders — while 24 added to existing stakes and 33 trimmed.
The largest buyer was Yong Rong (HK) Asset Management, opening a new position worth an estimated $32.7M. The largest seller was Tieton Capital Management, cutting an estimated $6.68M.
- 96 institutional investors held Niagen Bioscience (NAGE) as of Q1 2021, up from 83 in Q4 2020.
- Funds reported $211M of Niagen Bioscience stock for Q1 2021, up 177% quarter-over-quarter.
- 29 funds opened new Niagen Bioscience positions in Q1 2021 and 16 closed out, a net change of +13 holders.
- The largest Niagen Bioscience buyer in Q1 2021 was Yong Rong (HK) Asset Management, an estimated $32.7M added.
- The largest Niagen Bioscience seller in Q1 2021 was Tieton Capital Management, an estimated $6.68M sold.
Based on aggregated 13F filings for Q1 2021.